Everest Medicines, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug ...

A California-based healthcare company is turning heads mid-week after it announced that it will be cutting its workforce by ...

Luminary Therapeutics today announced that it has been awarded up to $5.8 million in funding from the Advanced Research Projects Agency for Health (ARPA-H), an agency within the U.S. Department of ...

VUMC received up to $30M to develop AI for antibody therapy discovery, aiming to create an antibody-antigen atlas and ...

Bacteria navigate tradeoffs between phage resistance and interbacterial competition. This study reveals that while LPS ...

An ambitious project led by Vanderbilt University Medical Center investigators aims to use artificial intelligence technologies to generate antibody therapies against any antigen target of interest.

The occurrence of long-chain polar residues Asn and Gln is slightly less pronounced in epitopes than in the antigen surfaces, while Ser residue is depleted. Conversely, the backbone polar atoms have a ...

Engineering a patient's own T cells to express chimeric antigen receptors (CARs) has cured patients with cancer refractory to all treatments. Decades ago, as this modality was being developed, there ...

The rarest blood type is Rhnull. Unlike other blood types, people with Rhnull blood have no Rh antigens on their red blood cells. Healthcare professionals classify blood type according to the ...

PINK1 is not the only important T cell target, or "antigen," in patients with Parkinson's disease. Previous research led by Sette and Lindestam Arlehamn showed that many Parkinson's disease ...

Merck & Co. has penned a $300 million biobucks-per-product deal with cancer biotech Epitopea to identify previously secret antigens that could form the backbone of off-the-shelf immunotherapies.